Oxivax - AOI #28: influenza vaccine innovation. Advancing metagenomic next-generation sequencing based agnostic diagnostics for viral pathogens the overall objective of this contract is to prepare the…
Active Definitive Contract Awarded Last action
- Contract number
- 75A50125C00006
- Awardee
-
Osivax UEI M4YDKJJRJYC7
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $743,969
Award facts
- Contract value 100% obligated
- $743,969.31 Current and potential, with all options
- Completion date 73% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- France
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $743,969 |
About this award
The Office of the Assistant Secretary for Preparedness and Response awarded a $743,969.31 firm fixed-price definitive contract to Osivax for preparation of an Investigational New Drug package for OVX836+SQ adjuvant, a single-shot broadly protective influenza A vaccine, on September 30, 2025.
Place of performance is France. The contract has an ultimate completion date of March 31, 2027. The originating solicitation, designated OXIVAX – AOI #28, focuses on influenza vaccine innovation and advancing metagenomic next-generation sequencing based agnostic diagnostics for viral pathogens, with the overall objective of preparing the IND package for OVX836+SQ adjuvant to support regulatory advancement toward FDA approval or licensure.
Description
Oxivax - AOI #28: influenza vaccine innovation. Advancing metagenomic next-generation sequencing based agnostic diagnostics for viral pathogens the overall objective of this contract is to prepare the IND package for OVX836+SQ adjuvant.
Quick answers
Who was awarded contract 75A50125C00006?
75A50125C00006 was awarded to Osivax by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 30, 2025.
How much is contract 75A50125C00006 worth?
The government has obligated $743,969 on 75A50125C00006.
Was contract 75A50125C00006 competed?
The extent of competition for 75A50125C00006 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award